Sun Pharmaceutical plans to acquire US-based Organon in an all-cash transaction valued at $11.75 billion, marking one of the biggest overseas acquisitions by an Indian pharmaceutical company.
Key Highlights
- Sun Pharmaceutical to acquire Organon for $11.75 billion, marking one of India’s largest pharma deals abroad.
- Deal strengthens biosimilars and women’s health portfolio, boosting global scale and long-term growth strategy.
Under the agreement, Sun Pharmaceutical will purchase all outstanding shares of Organon at $14 per share in cash. The deal has received approval from the boards of both companies and is expected to close in early 2027, subject to regulatory and shareholder approvals.
The acquisition is a major step in Sun Pharma’s strategy to diversify beyond its traditional generics business and strengthen its presence in innovative medicines and biosimilars.
Organon brings a portfolio of more than 70 products across women’s health and general medicine, with operations spanning over 140 countries-significantly expanding Sun Pharma’s global reach.
Following the acquisition, the combined entity is expected to generate annual revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally. It is also projected to become a top-three player in women’s health and among the top seven companies in the biosimilars segment.
Also Read: Wipro to Acquire Singapore Olam's IT Unit for $375 Million
Financial Details and Deal Structure
Organon reported revenue of approximately $6.2 billion in 2025 and carries debt of about $8.6 billion, alongside cash reserves of $574 million.
Sun Pharmaceutical said it will finance the acquisition through a mix of internal cash reserves and committed bank funding. The deal will be executed by merging Organon with a Sun Pharma subsidiary, with Organon continuing as the surviving entity.
Sun Pharmaceutical Chairman Dilip Shanghvi described the acquisition as a “significant opportunity” to build a more diversified global platform, adding that Organon’s capabilities are highly complementary to Sun Pharma’s portfolio.
Organon Executive Chair Carrie Cox said the transaction delivers “compelling and immediate value” to shareholders while positioning the company for its next phase of growth.
